NO943967L - Suppresjon av proliferative responser og induksjon av toleranse med polymorf klasse II MHC allopeptider - Google Patents

Suppresjon av proliferative responser og induksjon av toleranse med polymorf klasse II MHC allopeptider

Info

Publication number
NO943967L
NO943967L NO943967A NO943967A NO943967L NO 943967 L NO943967 L NO 943967L NO 943967 A NO943967 A NO 943967A NO 943967 A NO943967 A NO 943967A NO 943967 L NO943967 L NO 943967L
Authority
NO
Norway
Prior art keywords
suppression
tolerance
induction
proliferative responses
polymorphic class
Prior art date
Application number
NO943967A
Other languages
English (en)
Norwegian (no)
Other versions
NO943967D0 (no
Inventor
Howard L Weiner
David A Hafler
Charles B Carpenter
Mohamed Sayegh
Zhengi Zhang
Original Assignee
Autoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autoimmune Inc filed Critical Autoimmune Inc
Publication of NO943967D0 publication Critical patent/NO943967D0/no
Publication of NO943967L publication Critical patent/NO943967L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
NO943967A 1992-04-20 1994-10-19 Suppresjon av proliferative responser og induksjon av toleranse med polymorf klasse II MHC allopeptider NO943967L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US87128992A 1992-04-20 1992-04-20
US96177992A 1992-10-15 1992-10-15
US97773792A 1992-11-13 1992-11-13
US08/027,127 US5593698A (en) 1990-10-31 1993-03-05 Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides
PCT/US1993/003708 WO1993020842A1 (en) 1992-04-20 1993-04-20 Suppression of proliferative response and induction of tolerance with polymorphic class ii mhc allopeptides

Publications (2)

Publication Number Publication Date
NO943967D0 NO943967D0 (no) 1994-10-19
NO943967L true NO943967L (no) 1994-10-19

Family

ID=27487557

Family Applications (1)

Application Number Title Priority Date Filing Date
NO943967A NO943967L (no) 1992-04-20 1994-10-19 Suppresjon av proliferative responser og induksjon av toleranse med polymorf klasse II MHC allopeptider

Country Status (13)

Country Link
US (1) US5593698A (de)
EP (1) EP0637249B1 (de)
JP (1) JPH07505892A (de)
KR (1) KR100275656B1 (de)
AT (1) ATE205400T1 (de)
AU (1) AU686101B2 (de)
BR (1) BR9306345A (de)
CA (1) CA2118502A1 (de)
DE (1) DE69330752D1 (de)
HU (1) HUT71310A (de)
IL (1) IL105472A (de)
NO (1) NO943967L (de)
WO (1) WO1993020842A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US6156306A (en) * 1994-08-17 2000-12-05 Albert Einstein College Of Medicine Of Yeshiva University Pancreatic β-cells for allogeneic transplantation without immunosuppression
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
US7361331B2 (en) * 1996-10-18 2008-04-22 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food Plant bioreactors
US6617171B2 (en) * 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
US7348005B2 (en) * 2000-03-15 2008-03-25 Advanced Research And Technology Institute Oral tolerance induction by collagen to prevent allograft rejection
AU2001245848A1 (en) * 2000-03-15 2001-10-23 Advanced Research And Technology Institute Oral tolerance induction by collagen to prevent allograft rejection
WO2001089557A2 (en) 2000-05-24 2001-11-29 The United States Of America, As Represented By Secretary Of The Department Of Health & Human Services Methods for preventing strokes by inducing tolerance to e-selectin
KR20030062321A (ko) 2000-08-21 2003-07-23 아피토프 테크놀러지 (브리스톨) 리미티드 펩티드 선별 방법
US7628988B2 (en) * 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
US7582313B2 (en) 2002-06-27 2009-09-01 The General Hospital Corporation Methods of organ regeneration using Hox 11-expressing pluripotent cells
US20040229785A1 (en) * 2002-11-15 2004-11-18 Denise Faustman Screening methods to identify treatments for autoimmune disease
US20080102054A1 (en) * 2005-01-18 2008-05-01 Faustman Denise L Compositions Containing Agm Cells And Methods Of Use Thereof
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
BRPI0815395A2 (pt) 2007-08-15 2015-02-10 Circassia Ltd Composição, vetor, produto, formulação farmacêutica, me´todo in vitro para determinar se as células t reconhecem um polipeptídeo, e, método in vitro para determinar se um indivíduo se encontra ou está em risco de uma condição.
JP6367836B2 (ja) 2013-02-07 2018-08-01 ザ ジェネラル ホスピタル コーポレイション Ｔ制御性細胞の増殖または枯渇方法
WO2015057968A2 (en) 2013-10-17 2015-04-23 The General Hospital Corporation Methods of identifying subjects responsive to treatment for an autoimmune disease and compositions for treating the same
US10137181B2 (en) * 2014-04-01 2018-11-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Isolated donor MHC-derived peptide and uses thereof
DK3447075T3 (da) 2015-05-15 2023-11-13 Massachusetts Gen Hospital Antagonistiske antistoffer af antitumornekrosefaktorreceptor-superfamilien
WO2017040312A1 (en) 2015-08-28 2017-03-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
WO2017059132A1 (en) 2015-09-29 2017-04-06 The General Hospital Corporation Methods of treating and diagnosing disease using biomarkers for bcg therapy
KR20250007678A (ko) 2016-05-13 2025-01-14 더 제너럴 하스피탈 코포레이션 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 항체
WO2020041361A1 (en) 2018-08-20 2020-02-27 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides
EP3880711A4 (de) 2018-11-15 2022-12-28 The General Hospital Corporation Agonistische polypeptide der tumornekrosefaktorrezeptorsuperfamilie

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364762A (en) * 1990-03-21 1994-11-15 Board Of Trustees Of The Leland Stanford Junior University Major histocompatibility complex (MHC) molecules

Also Published As

Publication number Publication date
EP0637249A4 (de) 1997-01-08
DE69330752D1 (de) 2001-10-18
ATE205400T1 (de) 2001-09-15
CA2118502A1 (en) 1993-10-28
KR950701228A (ko) 1995-03-23
BR9306345A (pt) 1998-06-30
NO943967D0 (no) 1994-10-19
WO1993020842A1 (en) 1993-10-28
EP0637249A1 (de) 1995-02-08
IL105472A (en) 1999-06-20
JPH07505892A (ja) 1995-06-29
HU9403006D0 (en) 1994-12-28
IL105472A0 (en) 1993-08-18
KR100275656B1 (ko) 2000-12-15
AU4108393A (en) 1993-11-18
US5593698A (en) 1997-01-14
EP0637249B1 (de) 2001-09-12
AU686101B2 (en) 1998-02-05
HUT71310A (en) 1995-11-28

Similar Documents

Publication Publication Date Title
NO943967D0 (no) Suppresjon av proliferative responser og induksjon av toleranse med polymorf klasse II MHC allopeptider
AU561016B2 (en) N-glycosylated carboxamide derivatives
IL85022A0 (en) Pyrazoline derivatives and their use as insecticides
HU912340D0 (en) Method for compensation of non-linear distortion of amplifier curcuits
ES8801788A1 (es) Un procedimiento para la preparacion de derivados de indol
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
ZA878633B (en) Antioxidant compositions and methods
NZ225976A (en) Method of preserving hay quality by addition of bacillus pumilus and compositions thereof
AU6417790A (en) Method and compositions for one-step cryopreservation of embryos
EP0753005A4 (de) Die regulation der aktivität zytotoxischer t-zelllymphozyten mit peptiden der mhc-klasse i
ES2002083A6 (es) Un metodo para preparar derivados de piroglutamida
DE4410136A1 (de) Tumorizide T-Lymphozyten
IN167848B (de)
DK313389A (da) Fremgangsmaade til opdraet af fisk og apparat til anvendelse derved
AU584585B2 (en) Herbicide
AU3027692A (en) Compositions for the treatment of mammalian diseases
IT1145272B (it) Composizione e procedimento per il trattamento di carelli e parrucche
IL89901A (en) Strobilurine derivative
EP0301449A3 (en) Enantiomers of propafenone-containing therapeutic agents
AU588227B2 (en) Hair growth stimulating agents and their use
MY131097A (en) Pharmaceutical compositions comprising interleukin-2
UA42901A1 (uk) Спосіб отримання порошкових постійних магнітів системи fe-nd-b
AU7481391A (en) Engrafting allogeneic tissues or organs using interleukin
AU5605890A (en) Continuous release phenylethanolamine derivative compositions
DE69117974D1 (de) Pharmazeutische zusammensetzungen zur behandlung von b-zell-entartungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application